n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2009

Elan Announces Filing Of Annual Report On Form 20-F For Year Ended December 31, 2009

Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2009.

Medivation Poised for Volatile Spring

Medivation's stock price will rocket -- or crash -- when test results for its Alzheimer's drug Dimebon arrive sometime this spring.

Biogen Says Tysabri Patient Additions Slow

Sales of the multiple sclerosis drug exceed $1 billion in 2009, but patient growth slows in fourth quarter.

Five Biotech Events to Watch in 2010

Five Biotech Events to Watch in 2010

Our senior biotech columnist offers his picks for the five biggest stock-moving events for 2010.

Safety Dogs Elan Alzheimer's Drug; Seattle Genetics Finds New Partner: BioBuzz

Safety Dogs Elan Alzheimer's Drug; Seattle Genetics Finds New Partner: BioBuzz

Elan is forced to cut high doses of its Alzheimer's drug ELND005 from a mid-stage study, while Seattle Genetics hooks up with a Japanese drug maker.

Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz

Stocks will move if any of these unexpected events come true.

'Mad Money Lightning Round': Buy Bucyrus on Weakness

'Mad Money Lightning Round': Buy Bucyrus on Weakness

Cramer says China still works for the stock, which has more room on the upside.

Cramer's 'Mad Money' Recap: A Mystifying Bull Market (Final)

Cramer's 'Mad Money' Recap: A Mystifying Bull Market (Final)

Cramer told viewers to look at this bull market as a relay race with one sector handing off the rally baton to another. Click for news from Jim Cramer.

More PML Troubles for Biogen, Elan MS Drug: Biobuzz

More PML Troubles for Biogen, Elan MS Drug: Biobuzz

European regulators update reports of serious brain infection tied to Tysabri.

Midday Movers: Pump Up the Volume

Midday Movers: Pump Up the Volume

Several small-cap stocks were moving on above-average volume during Friday's session

Elan Swings to Third-Quarter Profit

Elan Swings to Third-Quarter Profit

The Irish drugmaker swung to third-quarter net income of $52.3 million, or 11 cents a share, as sales of its Tysabri drug rose.

Biogen Reports Higher Profit

Biogen Reports Higher Profit

Tysabri sales slightly beats expectations and lowers revenue guidance.

Onyx Pharma Holds Conference Call Too Late: BioBuzz

Onyx Pharma Holds Conference Call Too Late: BioBuzz

Why wait one week to discuss good breast cancer data?

Orexigen Moves Forward With 2nd Obesity Drug: BioBuzz

Orexigen Moves Forward With 2nd Obesity Drug: BioBuzz

A midstage study of Empatic demonstrates significant weight loss.

New Breast Cancer Data from Onyx Pharma: BioBuzz

New Breast Cancer Data from Onyx Pharma: BioBuzz

Nexavar study results not as strong as those posted last week.

Oculus Insider to Sell Microcyn: BioBuzz

Oculus Insider to Sell Microcyn: BioBuzz

Oculus turns to a director and large shareholder for Microcyn marketing help.

FDA Sends More Bad News to Repros: BioBuzz

FDA Sends More Bad News to Repros: BioBuzz

Proellex's future is in doubt after it received a letter from the FDA.

Citigroup, Best Buy: Tuesday's Headlines

Citigroup, Best Buy: Tuesday's Headlines

Tuesday's early headlines include reports that the government will begin to unload its 34% stake in Citigroup, a report that Chrysler will see a sharp decline in sales for September, and earnings from Best Buy and Kroger.

Elan Revises Partnership Deal With J&J

Elan said Johnson & Johnson will cut the value of a partnership deal to $885 million after Elan said it repaired a breach in its Tysabri agreement with Biogen Idec.

Sprint, J&J: Monday's Headlines

Sprint, J&J: Monday's Headlines

Monday's early headlines include a report Deutsche Telekom will launch a bid for Sprint Nextel, a separate report that Johnson & Johnson is looking to shave $100 million off its deal for Elan, and President Obama set to deliver remarks on the financial sector and regulation.

J&J Renegotiating Elan Deal: Report

J&J Renegotiating Elan Deal: Report

Johnson & Johnson is trying to lower the price of its deal with Irish biotech outfit Elan in the wake of a court ruling, according to a media report.

Hot Biotech Events for Next Week: BioBuzz

Investor conferences and phase III data on tap for post-Labor Day

Elan Commits to J&J Despite Tysabri Ruling

The Irish drugmaker said it's committed to close a transaction with Johnson & Johnson as quickly as possible following a judge's ruling it has breached an agreement with Biogen for the marketing of Tysabri.

Don't Fret Over Allos Weakness: BioBuzz

Allos Therapeutics' lymphoma drug will be approved and used.

Biotech Mailbag: Biocryst, Anadys, Allos, Amag

Readers weigh in on Biocryst's flu drug, the forecast for Alzheimer's drugs, Allos' prognosis, and why AMAG's stock is getting pummeled.

'Mad Money Lightning Round': Hold Onto SanDisk

Cramer says the company will be in a good position after an elimination of a glut of flash memory.

Cramer's 'Mad Money' Recap: Plight of Money Managers (Final)

Cramer says money managers are feverishly buying on dips to get back into the market. Click for news from Jim Cramer.

Elan Narrows Loss as Tysabri Sales Rise

Elan Narrows Loss as Tysabri Sales Rise

The Irish drugmaker reported a narrower second-quarter loss as sales of multiple sclerosis drug Tysabri rose 30%.

Biogen Earnings Fall, Tysabri Tops Views

Biogen Earnings Fall, Tysabri Tops Views

Biogen Idec reported an 18% drop in adjusted second-quarter earnings, impacted by a one-time payment related to a recent drug-licensing deal, but sales of its multiple sclerosis drug Tysabri topped Wall Street expectations.

Biotech Stock Mailbag: Chelsea Therapeutics

Biotech Stock Mailbag: Chelsea Therapeutics

Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.